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Purpose: To review the most recent published data regarding the novel potent steroid, 
  difluprednate ophthalmic emulsion, 0.05%.
Methods: A comprehensive search of recent published literature including difluprednate was 
performed. Clinical studies relevant to the characteristics and clinical efficacy of difluprednate 
in controlling postoperative inflammation were included, and a synopsis of each study was 
developed.
Results: Several recent publications were identified in which difluprednate was shown to be 
efficacious in the treatment of postoperative inflammation in different clinical settings, including 
a novel perioperative regimen. Additional literature retrieved from this search included data on 
the relative potency of difluprednate, potential utility in the posterior segment, as well as the 
advantages of the emulsion formulation.
Conclusion: Difluprednate has been studied extensively and shown in recent literature to be a 
safe and effective topical anti-inflammatory drug. The proven strength and unique formulation 
of difluprednate, along with its potent efficacy in treating and preventing inflammation, provides 
clinicians with a beneficial treatment option.
Keywords: corticosteroids, anti-inflammatory, dose uniformity, relative potency
Introduction
Controlling and preventing inflammation is the most important concern of the 
ophthalmologist in achieving optimal results following surgery. The physician can 
proactively help to reduce the risk of inflammation that can occur after the operation 
takes place. Even though some ocular surgeries, such as phacoemulsification, do not 
generally result in significant inflammation, there are still a portion of patients that 
will experience some form of postoperative inflammation, which can potentially lead 
to sight-threatening issues such as cystoid macular edema.1 As such, the majority of 
physicians employ a prophylactic regimen of anti-inflammatory medications in the 
perioperative period. Because of their broad anti-inflammatory activity, corticosteroids 
are typically the cornerstone of these treatment regimens.
Almost 3 years ago, a potent new steroid – difluprednate ophthalmic emulsion, 
0.05% (Durezol®, Alcon Laboratories, Inc, Fort Worth, TX) – was approved by the US 
Food and Drug Administration for the treatment of inflammation and pain associated 
with ocular surgery.2 Since then, many physicians have had extensive clinical experi-
ence with difluprednate and have incorporated it into their standard anti-inflammatory 
treatment regimen. Because of the increased awareness and subsequent use of this 
steroid, many studies exploring the characteristics and efficacy of difluprednate have Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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recently been published. This review will provide a summary 
of recent publications covering dose uniformity, relative 
potency, and clinical utility of this new steroid in different 
clinical settings.
Difluprednate dose uniformity
Due to the lipophilic nature of steroid molecules, and 
  therefore their inability to dissolve in a solution, the   majority 
of steroid preparations are formulated as suspensions. 
Ophthalmic suspensions tend to settle over time, and as a 
result, must be shaken by the patient prior to use to ensure a 
homogenous distribution of active drug within the aqueous 
phase of the suspension. If a bottle of a suspension formula-
tion is not shaken, the drops may have subtherapeutic levels 
of corticosteroid, even in the first days postoperatively when 
anti-inflammatories are typically needed most. Unfortunately, 
as most clinicians know, patients are not very compliant when 
it comes to shaking their medication. This was borne out of a 
study of steroid preparations, in which only 37% of patients 
followed the prescribed shaking instructions.3 In addition, 
even when patients appropriately shake their medication, 
particles within the suspensions still have a tendency to 
agglomerate or cake, especially as the particle size of the 
drug increases. The potential lack of homogeneity with sus-
pensions can lead to dosage inconsistencies. Difluprednate 
ophthalmic emulsion was formulated as a stable oil-in-water 
emulsion to achieve optimum dosage consistency. Stringer 
and Bryant conducted a study to determine whether the posi-
tion and shaking of a bottle affected the amount of active 
ingredient delivered.4 Three topical steroids – difluprednate 
ophthalmic emulsion, generic prednisolone acetate suspen-
sion 1% (Falcon Pharmaceuticals, Ltd, Fort Worth, TX), and 
branded prednisolone acetate suspension 1% (Pred Forte®, 
Allergan, Inc, Irvine, CA) – were stored upright and either 
shaken or not shaken, or were stored upside down and not 
shaken. Two drops were dosed four times a day to simulate 
patient use, and were then measured for the amount of active 
drug delivered in each drop. The dose uniformity of diflu-
prednate was excellent regardless of bottle storage position 
or shaking before use. All doses were close to 100% of the 
stated label claim.
Generic prednisolone acetate suspension exhibited very 
poor dose uniformity, and after inverted storage and no 
shaking trended from very high concentrations (more than 
700% of label claim) on day 1 to very low concentrations 
after 1 week, most of which were subtherapeutic levels. 
Even in ideal conditions – stored upright and shaken – it 
demonstrated significant variability in dose concentration. 
The branded version of prednisolone acetate also exhibited 
similar trends, although not as extreme. Table 1 shows the 
percentage of drops that were within 15% of declared con-
centration for all conditions tested. All doses of difluprednate 
remained within this range 100% of the time, no matter the 
orientation or handling of the bottle. In contrast, generic 
prednisolone acetate concentrations were within 15% of 
declared concentration for only 4%–13% of the time points, 
depending on the condition tested.
Difluprednate ophthalmic emulsion demonstrated excel-
lent and consistent dose uniformity compared with the sus-
pensions, suggesting that the clinical use of difluprednate 
may produce more predictable efficacy and safety.
Difluprednate potency
Glucocorticoid receptor-binding activity (GCRBA) is an 
important measure widely accepted as an index of pharma-
cologic effect. Tajika et al conducted a study to determine 
the GCRBA of difluprednate ophthalmic emulsion and its 
active metabolite, 6α,9-difluoroprednisolone 17-butyrate 
(DFB), compared with prednisolone, betamethasone, 
  fluorometholone, and dexamethasone.5 A glucocorticoid 
receptor-binding test was performed to evaluate the Ki value 
of each steroid, which is an inhibition constant that indicates 
the affinity for a receptor. A lower Ki value indicates a stron-
ger affinity for the glucocorticoid receptor. The results of this 
study most notably showed that DFB, the active metabolite of 
difluprednate ophthalmic emulsion, had the lowest Ki value 
(6.11 × 10-11 mol/L) and was significantly more active than 
prednisolone, which had a Ki value of 3.4 × 10-9 mol/L. This 
demonstrates that the glucocorticoid binding affinity for the 
active metabolite of difluprednate was 56 times stronger 
than prednisolone.
The greater binding affinity may be attributed to the 
unique molecular structure of difluprednate. Difluprednate 
is a derivative of prednisolone but differs substantially due to 
structural modifications. The first is the addition of fluorine 
Table  1  Percentage  of  data  points  within  15%  of  declared 
concentration4
Usage condition Pred Forte® Durezol® Generic  
prednisolone
Upright, not shaken 54% 100% 13%
Upright, shaken 40% 100% 6%
inverted, not shaken 0% 100% 4%
Copyright © 2010, Stringer and Bryant.4 Reproduced with permission from Dove 
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atoms at the C-6 and C-9 positions. It is   well-known that 
fluorination of corticosteroids greatly increases   specificity 
for the glucocorticoid receptor6 and many of the more-
powerful   glucocorticoids are fluorinated at either the C-6 
or C-9 position (eg, betamethasone, clobetasol), or at both 
(eg, fluticasone). Difluprednate is the only difluorinated 
topical ophthalmic glucocorticoid available in the US. 
The second modification is the addition of a butyrate ester 
at the C-17 position. This has also been shown to further 
increase the potency of difluprednate.7 Thus, the first two 
modifications – the addition of the two fluorines and of the 
C-17 butyrate – directly increase the affinity of difluprednate 
for the glucocorticoid receptor. While receptor binding is 
important, it is not the only determinant of therapeutic effec-
tiveness. In the case of a topical ophthalmic steroid, the drug 
must also have access to the receptor at the site of inflam-
mation. The third modification of difluprednate increases its 
ability to reach the relevant ocular glucocorticoid receptors. 
Previous work has shown that the corneal penetration of glu-
cocorticoids is enhanced by the addition of an acetate group 
to the molecule.8 In difluprednate, the addition of the acetate 
ester at position C-21 enhances tissue penetration, enabling 
more active drug to reach the uvea. In fact, glucocorticoids 
with 17,21-double esters, such as difluprednate, generally 
penetrate tissue better than monoester derivatives.9
Safety
All ophthalmic corticosteroids, both topical and systemic, 
have the potential to provoke a rise in intraocular pressure 
(IOP), especially in patients with certain risk factors, such as 
myopia, diabetes, and family history of glaucoma. Genetic 
factors likely also exist that confer a risk of IOP elevation 
secondary to corticosteroid exposure. Difluprednate is no 
different in this regard; that is, it can also be associated 
with elevated IOP. Thus, standard of care practices must be 
employed, with frequent measurement of eye pressure for 
anyone using this medication.
As a general rule, the more powerful the steroid, the 
more prevalent the adverse events. In several clinical trials 
where Durezol was dosed either QID or BID for a median 
time of 27.1 days, a 3%–6% rate of clinically significant 
IOP elevation was evident, defined as a rise in IOP of more 
than 21 mmHg and at least 10 mmHg from baseline at the 
same visit. While this rate is in line with other moderate-to-
strong steroids, there have been anecdotal and unpublished 
accounts of pressure increases that are of greater intensities 
than what is typically seen with this class. However, its 
enhanced potency, which permits less frequent dosing than 
prednisolone, and its emulsion formulation, which does 
not require shaking the bottle to resuspend the drug, make 
  difluprednate a major advancement in patient compliance 
and inflammatory control. Difluprednate is highly likely to 
become the preferred product for most eye care specialists 
who manage all types of intraocular inflammation, despite 
the universal caution of IOP increase that accompanies all 
steroid use.
Difluprednate in postoperative 
inflammation
Recently, my colleagues and I conducted a study testing a 
novel steroid pulse-dosing regimen. This study was designed 
based upon the use of steroids in other medical disciplines 
outside of ophthalmology. In a large systematic review that 
analyzed numerous randomized controlled clinical trials 
involving major surgical procedures, the administration of 
a steroid prior to surgery reduced local edema and pain in 
many of the procedures.10 It was found that the timing of 
steroid administration was critically important – steroids 
dosed less than 1–2 hours prior to surgery seemed to have 
less effect, potentially because the protein-mediated onset of 
action for steroids takes about this long. In addition, the large 
National Acute Spinal Cord Injury trial demonstrated that 
the administration of high-dose steroids immediately after 
surgery helps to preserve and protect neural tissue.11 Based 
on these two concepts, my colleagues and I tested a regimen 
in which two steroids (difluprednate ophthalmic emulsion 
and prednisolone acetate suspension) were dosed at least 
10 times on the day of cataract surgery, and then continued 
for 2 weeks postoperatively.12 Our study was a prospective 
multicenter, double-masked, randomized, contralateral-eye 
trial conducted in 63 patients (126 eyes). We found that the 
administration of difluprednate in this pulse-dosing fashion 
provided better vision and less corneal edema (measured via 
pachymetry) on day 1 when compared with prednisolone. On 
the first day after surgery, 19 patients in the difluprednate 
arm and six patients in the prednisolone arm had a best cor-
rected visual acuity (BCVA) of 20/20. Table 2 shows the 
uncorrected visual acuity (UCVA) and BCVA at day 1 for 
the two regimens.
The mean central corneal thickness at day 1 in the diflu-
prednate group increased 28 µm (from 562 to 590 µm). This 
increase was about half of that observed in the prednisolone 
group, which was 57 µm (from 562 to 619 µm). Addition-
ally, central corneal thickness at day 1 in the difluprednate Clinical Ophthalmology 2011:5 submit your manuscript | www.dovepress.com
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group averaged 32.59 µm less than that of the prednisolone 
group (P = 0.026). At day 1, corneal swelling in the diflupred-
nate group was 31.79 µm less than the prednisolone group 
(P = 0.033) compared with baseline.
One of the important secondary endpoints assessed was 
endothelial cell counts. In the difluprednate arm, there was 
significantly less endothelial cell loss at day 30 (Figure 1), 
with a difference of 180 cells between the two groups. This 
was interesting, since it shows that a pulse-dosing regimen 
may help to preserve endothelial cells, and that a more potent 
steroid may have an added effect.
In addition, OCT measurements revealed thinner retinas 
at days 15 and 30 in the difluprednate group (Figure 2). By 
day 15, the mean retinal thickness in the eyes treated with 
difluprednate was 7.74 µm less than the prednisolone treated 
eyes (P = 0.011). Similarly, by day 30, the mean retinal 
thickness of the difluprednate group was 5 µm less than the 
prednisolone group. This study not only demonstrates the 
utility of this pulse-dosing regimen, but also demonstrates 
the clinical potential of this new topical steroid. Furthermore, 
a recent anterior uveitis study conducted by Foster et al 
showed that difluprednate dosed four times a day exhibited a 
potent anti-inflammatory effect when compared with branded 
prednisolone acetate (Pred Forte®) dosed eight times a day.13 
We now have a steroid that achieves similar clinical results at 
half the dose or less of our old standard treatment.
Difluprednate in the posterior 
segment
In a recently published preclinical study by Tajika et al, a 
single instillation of radiolabeled difluprednate resulted 
in detectable posterior segment levels (anterior retina/ 
choroid = 273 ngeq/g; posterior retina/choroid = 59 ngeq/g), 
suggesting that topical administration may have possible 
effectiveness in the posterior segment.14 While no large studies 
have specifically explored the use of difluprednate in retinal 
disease, two small case control studies published by Nakano 
et al demonstrate potential utility. In the first, Durezol was 
compared with a sub-Tenons injection of triamciniolone and 
was found to have similar effects at reducing retinal thickness 
in patients with refractory diabetic macular edema (DME).15 
In the second, Durezol was compared with betamethasone 
Table 2 UCvA and BCvA at day 1 in each treatment arm
Snellen visual acuity UCVA at day 1 
Number of subjects (percentage of subjects)
BCVA at day 1 
Number of subjects (percentage of subjects)
Difluprednate Prednisolone P-value Difluprednate Prednisolone P-value
20/20 or better 8 (16%) 2 (4%) NS 19 (38%) 6 (12%) P , 0.005
20/30 or better 28 (56%) 20 (40%) NS 43 (86%) 28 (56%) P , 0.005
20/40 or better 36 (72%) 32 (64%) NS 48 (96%) 41 (82%) P , 0.05
20/70 or better 47 (94%) 44 (88%) NS 50 (100%) 47 (94%) NS
20/100 or better 50 (100%) 48 (96%) NS 50 (100%) 48 (96%) NS
Abbreviations: BCVA, best corrected visual acuity; NS, not significant; UCVA, uncorrected visual acuity.
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Figure 1 The change from baseline endothelial cell counts of eyes treated with difluprednate or prednisolone.
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in treating diffuse DME prior to vitrectomy, and Durezol 
was found to reduce retinal thickness and improve VA more 
effectively than betamethasone after 1 month of treatment.16 
While these studies must be interpreted cautiously, due to 
their size and design, they provide interesting hypotheses. 
  Nonetheless, given Durezol’s high potency and strong affinity 
for the glucocorticoid receptor, there may be a place for this 
  topical steroid in treating posterior segment disease with an 
inflammatory component.
Conclusion
While several steroids have been introduced over the last 
few decades, difluprednate is the first to be more potent than 
prednisolone acetate, which has been considered the “gold 
standard” and indeed has enjoyed a status as the “go-to” 
steroid for many inflammatory conditions.
Although cataract surgery complications are generally 
rare, approximately 5% of patients will experience problems 
after surgery, ranging from mild and transient conditions to 
more sight-threatening issues that require further   treatment.1 
During the past decade, advances in cataract surgery tech-
niques, equipment, and pharmacologic strategies have 
helped to keep the rate of complications low. Nonetheless, 
complications still occur, and in an effort to prevent these, 
most physicians will prophylactically treat patients with a 
standard perioperative regimen to prevent infections and 
reduce postoperative inflammation and pain.
With the proven efficacy of difluprednate, as is evident 
from these reviewed publications, we now have a new stan-
dard for potency in a topical corticosteroid, with excellent 
anti-inflammatory properties and an ideal formulation for 
our patients.
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